Reporter brief
RCT of semaglutide and tirzepatide on epigenetic aging in 66 adults with obesity over 24 weeks
What happened
This prospective randomized open-label trial enrolled 66 adults with obesity who had not used weight-loss medications for at least 3 months. Participants received semaglutide, tirzepatide, or metformin for 24 weeks. The study measured changes in epigenetic (biological) age using iWatchAge DNA methylation testing and tracked aging-related biomarkers including inflammatory factors, metabolic parameters, and body composition.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Adults with simple obesity who have not used weight-loss medications for at least 3 months
- Design
- Rct
- Sample
- 66
- Journal
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Published
- Dec 19, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.